Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
Revenue (TTM)
$12 Mln
Net Profit (TTM)
$-2 Mln
ROE
-4.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.1
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
-1.1
Book Value
$--
EPS
$-30.3
Face value
--
Shares outstanding
2,828,350
CFO
$-257.10 Mln
EBITDA
$-293.76 Mln
Net Profit
$-307.87 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ASLAN Pharmaceuticals - ADR
| -85.6 | -56.5 | -81.3 | -96.4 | -82.6 | -64.6 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
ASLAN Pharmaceuticals - ADR
| -71.0 | -67.9 | -38.8 | -9.9 | -43.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ASLAN Pharmaceuticals - ADR
|
0.6 | 1.7 | 12.0 | -35.0 | -184.0 | -- | -- | 2.1 |
| 45.0 | 8,191.5 | 16.5 | -460.5 | -2,791.7 | -110 | -- | 14.5 |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal... antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore. Read more
Founder, CEO & Executive Director
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.
Founder, CEO & Executive Director
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.
Headquarters
Singapore
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ASLAN Pharmaceuticals Limited - ADR is $0.60 (NASDAQ) as of 16-Aug-2024 09:30 EDT. ASLAN Pharmaceuticals Limited - ADR has given a return of -82.56% in the last 3 years.
Since, TTM earnings of ASLAN Pharmaceuticals Limited - ADR is negative, P/E ratio is not available.
The P/B ratio of ASLAN Pharmaceuticals Limited - ADR is 2.14 times as on 16-Aug-2024, a 46 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-5.19
|
-17.28
|
|
2022
|
0.00
|
0.02
|
|
2021
|
-0.02
|
0.01
|
|
2020
|
-0.04
|
-0.07
|
|
2019
|
-0.29
|
-8.17
|
The 52-week high and low of ASLAN Pharmaceuticals Limited - ADR are Rs -- and Rs -- as of 03-Apr-2026.
ASLAN Pharmaceuticals Limited - ADR has a market capitalisation of $ 2 Mln as on 16-Aug-2024. As per SEBI classification, it is a Small Cap company.
Before investing in ASLAN Pharmaceuticals Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$--
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.